3.43
price up icon1.48%   0.05
after-market Handel nachbörslich: 3.44 0.010 +0.29%
loading
Schlusskurs vom Vortag:
$3.38
Offen:
$3.37
24-Stunden-Volumen:
41,716
Relative Volume:
1.51
Marktkapitalisierung:
$102.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.77M
KGV:
-23.07
EPS:
-0.1487
Netto-Cashflow:
$-1.46M
1W Leistung:
-2.00%
1M Leistung:
-4.99%
6M Leistung:
-32.75%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$3.15
$3.445
1-Wochen-Bereich:
Value
$3.09
$3.6091
52-Wochen-Spanne:
Value
$2.5701
$26.50

Turn Therapeutics Inc Stock (TTRX) Company Profile

Name
Firmenname
Turn Therapeutics Inc
Name
Telefon
(818) 564-4011
Name
Adresse
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Name
Mitarbeiter
2
Name
Twitter
Name
Nächster Verdiensttermin
2026-04-02
Name
Neueste SEC-Einreichungen
Name
TTRX's Discussions on Twitter

Compare TTRX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
TTRX icon
TTRX
Turn Therapeutics Inc
3.43 100.68M 0 -1.77M -1.46M -0.1487
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-12-29 Eingeleitet D. Boral Capital Buy

Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten

pulisher
Apr 06, 2026

Bradley Burnam holds 52.76% of Turn Therapeutics (NASDAQ: TTRX) common stock - Stock Titan

Apr 06, 2026
pulisher
Apr 06, 2026

Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX) - Defense World

Apr 06, 2026
pulisher
Apr 03, 2026

Athersys and Turn Therapeutics Battle for Biotech Supremacy - National Today

Apr 03, 2026
pulisher
Apr 03, 2026

Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Director at Turn Therapeutics (TTRX) makes bona fide gift of 300,000 shares - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Turn Therapeutics (TTRX) CEO receives 160,000 stock options at $3.43 strike - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

80K options granted at $3.12 to Turn Therapeutics (TTRX) - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

[EFFECT] Turn Therapeutics Inc. SEC Filing - Stock Titan

Apr 03, 2026
pulisher
Apr 02, 2026

TTRX Stock Price, Quote & Chart | TURN THERAPEUTICS INC (NASDAQ:TTRX) - ChartMill

Apr 02, 2026
pulisher
Apr 01, 2026

Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results - MarketBeat

Apr 01, 2026
pulisher
Apr 01, 2026

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Apr 01, 2026
pulisher
Apr 01, 2026

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - BioSpace

Apr 01, 2026
pulisher
Mar 31, 2026

Turn Therapeutics (TTRX) registers up to 7,000,000 shares for GEM resale - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Turn Therapeutics (TTRX) registers 17.87M shares for resale by stockholders - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Turn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026
pulisher
Mar 31, 2026

Turn Therapeutics (TTRX) details eczema drug plans and going-concern risk - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Turn Therapeutics (NASDAQ: TTRX) widens 2025 loss but secures $25M growth capital - Stock Titan

Mar 31, 2026
pulisher
Mar 30, 2026

Turn Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 30, 2026
pulisher
Mar 25, 2026

TTRX SEC FilingsTurn Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart

Mar 25, 2026
pulisher
Mar 24, 2026

Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN

Mar 24, 2026
pulisher
Mar 24, 2026

D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Ana - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics Secures Growth Capital to Advance Dermatology - tipranks.com

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - MarketScreener

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Turn Therapeutics Inc. (TTRX) - Minichart

Mar 24, 2026
pulisher
Mar 23, 2026

Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener

Mar 23, 2026
pulisher
Mar 23, 2026

Turn Therapeutics Inc. (TTRX) AI-Powered Stock Analysis - Meyka

Mar 23, 2026
pulisher
Mar 21, 2026

Turn Therapeutics Inc. (TTRX) Stock forecasts - Yahoo Finance UK

Mar 21, 2026
pulisher
Mar 20, 2026

Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World

Mar 20, 2026
pulisher
Mar 16, 2026

Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga España

Mar 16, 2026
pulisher
Mar 02, 2026

TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - MarketBeat

Mar 02, 2026
pulisher
Feb 25, 2026

TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha

Feb 25, 2026
pulisher
Feb 20, 2026

Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView

Feb 20, 2026
pulisher
Feb 17, 2026

Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks

Feb 17, 2026
pulisher
Feb 17, 2026

Turn appoints Dr. Robert Redfield as senior advisor to guide GX-03 regulatory and clinical strategy - TradingView

Feb 17, 2026
pulisher
Feb 17, 2026

Former CDC director joins Turn Therapeutics (TTRX) as senior health policy advisor - Stock Titan

Feb 17, 2026
pulisher
Feb 17, 2026

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Caledonian Record

Feb 17, 2026
pulisher
Feb 14, 2026

How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

TTRX Should I Buy - Intellectia AI

Feb 14, 2026
pulisher
Feb 13, 2026

Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent

Feb 13, 2026

Finanzdaten der Turn Therapeutics Inc-Aktie (TTRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
Kapitalisierung:     |  Volumen (24h):